Your browser is no longer supported. Please, upgrade your browser.
HOOK [NASD]
HOOKIPA Pharma Inc.
Index- P/E- EPS (ttm)-2.18 Insider Own0.30% Shs Outstand32.87M Perf Week-22.68%
Market Cap52.70M Forward P/E- EPS next Y-2.23 Insider Trans-12.42% Shs Float23.63M Perf Month-39.52%
Income-66.90M PEG- EPS next Q-0.57 Inst Own70.10% Short Float9.06% Perf Quarter-70.99%
Sales19.70M P/S2.67 EPS this Y29.70% Inst Trans-0.03% Short Ratio8.41 Perf Half Y-79.81%
Book/sh3.29 P/B0.46 EPS next Y4.30% ROA-40.20% Target Price9.94 Perf Year-88.26%
Cash/sh2.34 P/C0.64 EPS next 5Y5.00% ROE-50.50% 52W Range1.75 - 20.00 Perf YTD-35.62%
Dividend- P/FCF- EPS past 5Y- ROI-33.10% 52W High-92.50% Beta-
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin- 52W Low-14.29% ATR0.19
Employees109 Current Ratio4.50 Sales Q/Q-2.50% Oper. Margin- RSI (14)16.94 Volatility13.00% 9.14%
OptionableYes Debt/Eq0.05 EPS Q/Q-15.10% Profit Margin- Rel Volume4.26 Prev Close1.76
ShortableYes LT Debt/Eq0.02 EarningsNov 10 BMO Payout- Avg Volume254.73K Price1.50
Recom2.00 SMA20-31.71% SMA50-47.67% SMA200-80.45% Volume1,084,747 Change-14.77%
Nov-12-21Downgrade Morgan Stanley Overweight → Equal-Weight $6
Apr-08-21Initiated Morgan Stanley Overweight $19
Nov-03-20Initiated Truist Buy $21
Oct-26-20Initiated JMP Securities Mkt Outperform $19
Oct-19-20Resumed H.C. Wainwright Buy $16
Sep-27-19Initiated H.C. Wainwright Buy $15
May-13-19Initiated RBC Capital Mkts Outperform $23
May-13-19Initiated BofA/Merrill Buy $17
Jan-18-22 07:00AM  
Jan-04-22 07:00AM  
Dec-03-21 07:00AM  
Nov-12-21 07:00AM  
Nov-10-21 07:45AM  
06:30AM  
Nov-09-21 04:01PM  
Nov-04-21 03:01PM  
Nov-03-21 08:18AM  
Oct-26-21 09:33AM  
Oct-14-21 07:00AM  
Oct-07-21 04:05PM  
Sep-16-21 11:24AM  
Sep-15-21 08:43AM  
07:38AM  
07:00AM  
Sep-07-21 10:00AM  
Aug-27-21 09:00AM  
Aug-12-21 08:35AM  
07:00AM  
Aug-05-21 03:01PM  
05:30AM  
Aug-03-21 07:00AM  
Jul-26-21 11:01AM  
Jun-28-21 04:51AM  
Jun-10-21 07:30AM  
Jun-08-21 06:38AM  
Jun-07-21 06:00PM  
May-20-21 07:00AM  
May-19-21 08:36AM  
May-12-21 10:31AM  
07:00AM  
May-10-21 08:42AM  
May-05-21 03:00PM  
May-03-21 07:00AM  
Apr-29-21 07:00AM  
Apr-28-21 02:56AM  
Apr-14-21 08:00AM  
Apr-10-21 08:31AM  
Mar-18-21 08:25AM  
07:33AM  
07:00AM  
Mar-11-21 12:30PM  
Mar-09-21 07:00AM  
Mar-04-21 07:00AM  
Mar-03-21 07:00AM  
Feb-27-21 03:49AM  
Feb-16-21 07:00AM  
Jan-20-21 09:55AM  
Dec-11-20 04:20PM  
Dec-08-20 10:00PM  
04:01PM  
08:34AM  
Dec-07-20 11:33PM  
06:00AM  
Nov-30-20 06:00AM  
Nov-18-20 10:23AM  
Nov-15-20 08:26AM  
Nov-12-20 07:39AM  
07:15AM  
Nov-11-20 07:00AM  
Nov-03-20 07:00AM  
Oct-29-20 07:30AM  
Oct-26-20 10:08AM  
Oct-21-20 10:32AM  
Oct-19-20 08:00AM  
Sep-16-20 07:45AM  
07:00AM  
Sep-09-20 07:30AM  
Aug-13-20 10:35AM  
07:20AM  
07:00AM  
Aug-06-20 12:30PM  
Aug-04-20 07:00AM  
Aug-03-20 12:31PM  
07:00AM  
Jul-23-20 03:24PM  
Jun-22-20 07:15AM  
Jun-19-20 07:00AM  
Jun-17-20 07:00AM  
Jun-12-20 02:04PM  
Jun-11-20 08:34AM  
May-26-20 07:30AM  
May-17-20 09:31AM  
May-14-20 08:15AM  
07:00AM  
May-07-20 12:30PM  
May-04-20 07:00AM  
Apr-29-20 07:00AM  
Apr-21-20 07:00AM  
Apr-19-20 10:33AM  
Mar-19-20 07:00AM  
06:00AM  
Mar-10-20 08:15AM  
Feb-18-20 08:00AM  
Jan-15-20 09:53AM  
Jan-06-20 07:00AM  
Dec-30-19 07:30AM  
Dec-20-19 02:27PM  
Nov-25-19 08:00AM  
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Matushansky IgorChief Medical OfficerDec 21Option Exercise0.1022,8532,28591,544Jan 12 10:07 AM
Matushansky IgorChief Medical OfficerDec 21Sale2.4914,94937,22380,178Jan 12 10:07 AM
SOFINNOVA CAPITAL VI FCPR10% OwnerApr 21Sale11.60328,6203,812,3863,177,574Apr 23 04:30 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 29Sale13.6736,829503,5703,506,194Mar 31 04:06 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 26Sale13.6935,171481,6423,543,023Mar 31 06:01 AM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 25Sale13.1228,546374,5693,578,194Mar 29 04:01 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 24Sale13.7052,690721,6163,606,740Mar 26 07:12 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 23Sale13.9140,000556,4763,659,430Mar 25 06:13 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 22Sale14.5440,534589,2633,699,430Mar 24 06:16 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 19Sale14.60166,2302,427,7393,739,964Mar 23 04:31 PM